Multidisciplinary approach in treatment of recurrent gastrointestinal stromal tumors: a case report and literature review
https://doi.org/10.18027/2224-5057-2018-8-1-12-17
Abstract
Currently, the standard treatment of recurrent gastrointestinal stromal tumors (GIST) is life-long targeted therapy with tyrosine kinase inhibitors. Imatinib is administered as a first-line therapy. Due to the high mutational potential of tumor cells the secondary drug resistance develops in an overwhelming number of patients, which leads to the necessity of switching to second (sunitinib) and third (regorafenib) line therapy. In addition, the role of the surgical method in the complex treatment of advanced GIST has recently been updated. This article gives an example of long-term follow-up and treatment of a patient with recurrent small bowel GIST. The effectiveness of the combined approach in the treatment of this complex category of patients has been demonstrated.
About the Authors
R. V. Orlova
Saint Petersburg State University;
Saint Petersburg City Oncology Clinic
Russian Federation
oncologist, MD, DSc Med, Professor, Head of the Department of Oncology
Russian Federation
oncologist, MD, DSc Med, Professor, Head of the Department of Oncology
V. A. Kashchenko
Saint Petersburg State University;
L. G. Sokolov Memorial Hospital № 122
Russian Federation
oncologist, MD, DSc Med, Professor, Chief Surgeon
Russian Federation
oncologist, MD, DSc Med, Professor, Chief Surgeon
M. D. Khanevich
Saint Petersburg City Oncology Clinic
Russian Federation
oncologist, MD, DSc Med, Professor, Deputy Chief Surgery Doctor
Russian Federation
oncologist, MD, DSc Med, Professor, Deputy Chief Surgery Doctor
A. V. Khazov
Saint Petersburg City Oncology Clinic
Russian Federation
oncologist, Head of department
Russian Federation
oncologist, Head of department
M. I. Gluzman
Saint Petersburg State University
Russian Federation
oncology surgeon, post-graduate student of the Department of Faculty Surgery, Medical Faculty
Russian Federation
oncology surgeon, post-graduate student of the Department of Faculty Surgery, Medical Faculty
A. E. Zinkovskaya
Saint Petersburg City Oncology Clinic
Russian Federation
oncology surgeon
Russian Federation
oncology surgeon
References
1. Iorio N., Sawaya R.A., Friedenberg F.K. Review article: the biology, diagnosis and management of gastrointestinal stromal tumours. Aliment. Pharmacol. Ther. 2014. Vol. 39. No. 12. pp. 1376–1386.
2. Miettinen M., Lasota J. Gastrointestinal stromal tumors. Gastroenterol. Clin. North. Am. 2013. Vol. 42. No. 2. pp. 399–415.
3. Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat.Rev. Clin. Oncol. 2012. Vol. 9. pp. 351–358.
4. Vadakara J., von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol. Oncol. Clin. North. Am. 2013. Vol. 27. No. 5. pp. 905–920.
5. Hirota S., Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol. Int. 2006. Vol. 56. No. 1. pp. 1–9.
6. Serrano C., George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther.Adv. Med. Oncol. 2014. Vol. 6. No. 3. p. 115–127.
7. Shirley M., Keating G.M. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Drugs. 2015. Vol. 75. No. 9. pp. 1009–1017.
8. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014. Vol. 25. Suppl. 3. pp. 321–326.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guideline): soft tissue sarcoma. Version 1.2017. http://www.nccn.org.
10. Siddiqui M.A. A., Scott L. J. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs. 2007. Vol. 67. No. 5. pp. 805–820.
11. Heinrich M., Corless C., Blanke C. et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006. Vol. 24. pp. 4764–4774.
12. Heinrich M.C., Maki R.G., Corless C. L. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008. Vol. 26. pp. 5352–5359
13. Liegl B., Kepten I., Le C. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008. Vol. 216. pp. 64–74
14. Wang W. L., Conley A., Reynoso D. et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011. Vol. 67. pp. 15–24.
15. Guo T., Hajdu M., Agaram N.P. et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin. Cancer Res. 2009. Vol. 15. No. 22. pp. 6862–6870.
16. Deeks E.D., Keating G.M. Sunitinib. Drugs. 2006. Vol. 66. No. 17. pp. 2255–2266.
17. Kang Y.-K., Ryu M.-H., Yoo C. et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013. Vol. 14. pp. 1175-1182.
18. George S., Wang Q., Heinrich M.C. et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J. Clin. Oncol. 2012. Vol. 30. No.
19. pp. 2401–2407. 19. US FDA. Stivarga (regorafenib): prescribing information. 2015. http://www.fda.gov.
20. European Medicines Agency. Stivarga: summary of product characteristics. 2015. http://www.ema.europa.eu.
21. Demetri G.D., Reichardt P., Kang Y.-K. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013. Vol. 381. No. 9863. pp. 295–302.
22. Park S. J., Ryu M.H., Ryoo B.Y. et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann. Surg. Oncol. 2014. Vol. 21. pp. 4211–4217.
23. Sym S. J., Ryu M.H., Lee J. L. et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J. Surg. Oncol. 2008. Vol. 98. pp. 27–33.
24. Du C.Y., Zhou Y., Song C. et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur. J. Cancer. 2014. Vol. 50. pp. 1772–1778.
25. Wardelmann E., Losen I., Hans V. et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int. J. Cancer. 2003. Vol. 106. No. 6. pp. 887–895.
26. Wang C.M., Fu H., Zhao G. F. et al. Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation. Mol.Med. Rep. 2009. Vol. 2. No. 3. p. 455–460.
27. Spitaleri G., Biffi R., Barberis M. et al. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). OncoTargets Ther. 2015. Vol. 8. pp. 1997–2003.
Review
For citations:
Orlova R.V., Kashchenko V.A., Khanevich M.D., Khazov A.V., Gluzman M.I., Zinkovskaya A.E. Multidisciplinary approach in treatment of recurrent gastrointestinal stromal tumors: a case report and literature review. Malignant tumours. 2018;8(1):12-17. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-1-12-17
Views:
988
Email this article 